Related references
Note: Only part of the references are listed.Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study
E. L. Kneepkens et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2017)
Immunogenicity of tocilizumab in patients with rheumatoid arthritis
Johanna Sigaux et al.
JOINT BONE SPINE (2017)
Glucocorticoid-resistant polymyalgia rheumatica: pretreatment characteristics and tocilizumab therapy
Shunsuke Mori et al.
CLINICAL RHEUMATOLOGY (2016)
IL-6 as a keystone cytokine in health and disease
Christopher A. Hunter et al.
NATURE IMMUNOLOGY (2015)
Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients
Javier Loricera et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2015)
IL-6 biology: implications for clinical targeting in rheumatic disease
Leonard H. Calabrese et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
Serum macrophage migration inhibitory factor levels are correlated with response to tocilizumab therapy in patients with rheumatoid arthritis
Tsuyoshi Kasama et al.
RHEUMATOLOGY INTERNATIONAL (2014)
Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities
Juergen Scheller et al.
SEMINARS IN IMMUNOLOGY (2014)
A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy
Toshio Tanaka et al.
SEMINARS IN IMMUNOLOGY (2014)
IL-6 in Inflammation, Immunity, and Disease
Toshio Tanaka et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2014)
The Biology and Medical Implications of Interleukin-6
Toshio Tanaka et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients
B. Pesce et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
Mark C. Genovese et al.
JOURNAL OF RHEUMATOLOGY (2013)
Immune mechanisms in medium and large-vessel vasculitis
Cornelia M. Weyand et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
Blockade of Interleukin-6 Receptor Alleviates Disease in Mouse Model of Scleroderma
Shun Kitaba et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Therapeutic Targeting of the Interleukin-6 Receptor
Toshio Tanaka et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis
Maxime Samson et al.
ARTHRITIS AND RHEUMATISM (2012)
IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
Stefan Rose-John
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
The origins, function, and regulation of T follicular helper cells
Cindy S. Ma et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica
S. Unizony et al.
ARTHRITIS CARE & RESEARCH (2012)
Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis
Christian Beyer et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
In Vivo Effects of the Anti-Interleukin-6 Receptor Inhibitor Tocilizumab on the B Cell Compartment
Petra Roll et al.
ARTHRITIS AND RHEUMATISM (2011)
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Juergen Scheller et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
Helga Ellingsgaard et al.
NATURE MEDICINE (2011)
Integrated safety in tocilizumab clinical trials
Michael H. Schiff et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Blockade of Interleukin-6 Signaling Suppresses Not Only Th17 but Also Interphotoreceptor Retinoid Binding Protein-Specific Th1 by Promoting Regulatory T Cells in Experimental Autoimmune Uveoretinitis
Hiroshi Haruta et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease
Soken-Nakazawa J. Song et al.
BLOOD (2010)
Interleukin-6 Signaling in Liver-Parenchymal Cells Suppresses Hepatic Inflammation and Improves Systemic Insulin Action
F. Thomas Wunderlich et al.
CELL METABOLISM (2010)
Subset Analysis of Patients Experiencing Clinical Events of a Potentially Immunogenic Nature in the Pivotal Clinical Trials of Tocilizumab for Rheumatoid Arthritis: Evaluation of an Antidrug Antibody ELISA Using Clinical Adverse Event-Driven Immunogenicity Testing
Kay Stubenrauch et al.
CLINICAL THERAPEUTICS (2010)
Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance
V. B. Matthews et al.
DIABETOLOGIA (2010)
IL-6: Regulator of Treg/Th17 balance
Akihiro Kimura et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation
Shigeru Kotake et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Therapeutic Effects of Interleukin-6 Blockade in a Murine Model of Polymyositis That Does Not Require Interleukin-17A
Naoko Okiyama et al.
ARTHRITIS AND RHEUMATISM (2009)
Interleukin-6 Blockade Suppresses Autoimmune Arthritis in Mice by the Inhibition of Inflammatory Th17 Responses
Minoru Fujimoto et al.
ARTHRITIS AND RHEUMATISM (2008)
Gut, inflammation and osteoporosis: basic and clinical concepts
H. Tilg et al.
GUT (2008)
IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis
Satoshi Serada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Interleukin-6 regulates pancreatic α-cell mass expansion
Helga Ellingsgaard et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-α and IL-17
M. Hashizume et al.
RHEUMATOLOGY (2008)
Interleukin-6 and its receptor: from bench to bedside
Juergen Scheller et al.
MEDICAL MICROBIOLOGY AND IMMUNOLOGY (2006)
Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer
Stefan Rose-John et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2006)
Jak/STAT/SOCS signaling circuits and associated cytokine-mediated inflammation and hypertrophy in the heart
Andrew M. Terrell et al.
SHOCK (2006)
Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease
N Nishimoto et al.
BLOOD (2005)
IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation
RM McLoughlin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host
W Khovidhunkit et al.
JOURNAL OF LIPID RESEARCH (2004)
Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling
SJ Curnow et al.
JOURNAL OF IMMUNOLOGY (2004)
IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin
E Nemeth et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Differential regulation of neutrophil-activating chemokines by IL-6 and its soluble receptor isoforms
RM McLoughlin et al.
JOURNAL OF IMMUNOLOGY (2004)
Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE)
V Matthews et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis
H Nakahara et al.
ARTHRITIS AND RHEUMATISM (2003)
Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells
C Pasare et al.
SCIENCE (2003)
Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice
A Katsume et al.
CYTOKINE (2002)
Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress
C Tsigos et al.
JOURNAL OF PSYCHOSOMATIC RESEARCH (2002)
The paradigm of IL-6: from basic science to medicine
Tetsuji Naka et al.
ARTHRITIS RESEARCH & THERAPY (2002)
Tissue-specific autoregulation of the stat3 gene and its role in interleukin-6-induced survival signals in T cells
M Narimatsu et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein
JD Gillmore et al.
LANCET (2001)
IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation
SM Hurst et al.
IMMUNITY (2001)
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses
T Jostock et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Combined interleukin 6 and soluble interleukin 6 receptor accelerates murine liver regeneration
M Peters et al.
GASTROENTEROLOGY (2000)
IL-6 switches the differentiation of monocytes from dendritic cells to macrophages
P Chomarat et al.
NATURE IMMUNOLOGY (2000)
Activation-induced inhibition of interleukin 6-mediated T cell survival and signal transducer and activator of transcription 1 signaling
TK Teague et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
